- Home
- BUDA vs UNCY Comparison
BUDA vs UNCY Comparison
Compare BUDA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BUDA | UNCY |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | 39 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 145.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BUDA | UNCY |
|---|---|---|
| Price | $10.25 | $6.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 14.2K | ★ 489.9K |
| Earning Date | 03-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $407.73 |
| P/E Ratio | $24.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.61 | $0.47 |
| 52 Week High | $10.70 | $7.57 |
Technical Indicators
Market Signals| Indicator | BUDA | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 49.09 |
| Support Level | $8.83 | $6.48 |
| Resistance Level | $10.53 | $7.12 |
| Average True Range (ATR) | 0.63 | 0.42 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 56.88 | 41.22 |
Price Performance
Historical ComparisonAbout BUDA Buda Juice Inc. Common Stock
Buda Juice Inc operates in a competitive beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never pasteurized, never HPP- processed, never UV- treated and always cold.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.